Kinevant Sciences is researching a potential new drug for sarcoidosis - namilumab – which inhibits one of the key proteins believed responsible for granuloma formation and persistence in sarcoidosis.
In Episode 69 of the FSR Sarc Fighter Podcast, Kinevant CEO Bill Gerhart and Director of Patient Advocacy, Rayne Rodgers discuss the status of namilumab, and how you as a sarcoidosis patient can participate in the Phase 2 clinical trial, RESOLVE-Lung.
Click here for information on how to sign up for the clinical trial: https://bit.ly/3DaVsR6
ClinicalTrials.gov listing for RESOLVE-Lung: https://clinicaltrials.gov/ct2/show/NCT05314517
ClinicalTrials.gov listing for RESOLVE-Heart: https://clinicaltrials.gov/ct2/show/NCT05351554
Below is a transcript of the interview. It is auto-generated. Please excuse typos and misspellings.
John Carlin: Coming up on the Sarkfighter podcast, an exciting new potential treatment for Sarcoidosis.
Bill Gerhart: This particular protein is required for granuloma formation and persistence and that if we inhibit it, we can potentially make a significant difference in Sarkidosis.
John Carlin: The folks at Cotton are ah, researching a drug that is showing promise and shutting off the body's damaging response to the triggers of Sarcoidosis.
Bill Gerhart: So that's what I mean about a precision medicine and why we're so excited about the promise and potential of this particular drug for Sarcodosis.
John Carlin: That interview is coming up.
Bill Gerhart: This is the Sarkfighter Podcast, living with sarchoidosis and other rare diseases. Here's your host, John Carlin.
John Carlin: Hello and welcome to the Sarkfighter Podcast. I'm your host, John Carlin and this episode of the FSR. Sarcfighter podcast is brought to you by kind of antsciences sponsor of the Resolve long pulmonary sarcoidosis clinical trial. For more information, please visit www.sarcodosentrial.com. I do this podcast to offer my fellow shark fighters hope and to help you connect with other shark patients to hear their stories, understand how Sarcidosis affects their lives. Hopefully that helps you understand what you are up against and what you need to do to overcome whether it's the disease or the effects of the medicine or both. Before we jump into our interview today, I want to give you an opportunity to become a leader in the Sarcodosis community by sharing your story. A lot of people have done it here on the podcast, but FSR now is seeking dynamic, dedicated individuals impacted by Sarcodosis. To work alongside the newly launched FSR Global Sarcoidosis Clinic Alliance, volunteers would apply to become community outreach leaders. That's a new title. Who will share their Sarcodosis story with the public to empower others and raise awareness, or apply to be support group leaders, which would be a different category of leadership to facilitate inperson support group meetings at FSR Global Alliance Clinic alliance member locations. Applications are due September 30, which is coming up quickly, about a month from the day that I'm recording here in late August of 2022. Learn more by visiting the FSR website and there will be a link in the show notes, but it's www.stopsarcodosis.org gscaleaders. But another thing that we do here on the Sark Fighter podcast and these actually tend to be the most popular episodes, is talk to researchers and people in the pharmaceutical space about progress in fighting Sarcoidosis. Kind of spread that out, didn't I? Sarcoidosis, well, Sarcoidosis, you know what I mean. Today I have for you a solid dose of hope. The pharmaceutical company kind of Am is working on a drug called Namiliumab and if all goes well, you'll be hearing a lot about it in the coming months and hopefully longer. Now probably if it gets through all the trials and so forth, it'll change and it'll have a, uh, commercial name. And if all goes according to plan and this becomes a drug tha